-+ 0.00%
-+ 0.00%
-+ 0.00%

Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study

PUBT·08/12/2026 11:28:12
Listen to the news
Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study
  • Protalix highlighted profitability with net income of $22.1 million for the first half of 2026.
  • Cash and cash equivalents of $40.7 million as of June 30, 2026; no debt; no warrants.
  • Total revenues of $53.6 million year to date; included a $25 million Chiesi milestone in Q1 2026.
  • Second-quarter revenue from selling goods rose to $19.8 million, driven by Elfabrio sales.
  • PRX-115 Phase 2 trial in uncontrolled gout is enrolling; topline data targeted for 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.